LivaNova PLC (NASDAQ:LIVN) Receives Consensus Recommendation of “Buy” from Brokerages

LivaNova PLC (NASDAQ:LIVN) has received a consensus rating of “Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $69.17.

Several brokerages have issued reports on LIVN. Mizuho cut their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 25th. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research note on Monday, November 25th. Robert W. Baird upped their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Primecap Management Co. CA raised its holdings in LivaNova by 0.7% in the 2nd quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock worth $327,889,000 after purchasing an additional 44,049 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of LivaNova by 62.7% during the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after buying an additional 806,374 shares during the period. Geode Capital Management LLC raised its stake in LivaNova by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock worth $70,676,000 after buying an additional 8,331 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in LivaNova by 16.6% in the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock worth $49,130,000 after buying an additional 133,401 shares during the period. Finally, Magnetar Financial LLC boosted its position in LivaNova by 8.1% during the 2nd quarter. Magnetar Financial LLC now owns 814,452 shares of the company’s stock valued at $44,648,000 after acquiring an additional 61,114 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Trading Up 1.3 %

Shares of LIVN stock opened at $47.27 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.57 billion, a P/E ratio of 112.55 and a beta of 0.98. The business has a 50-day moving average price of $50.28 and a two-hundred day moving average price of $50.61. LivaNova has a 12-month low of $43.15 and a 12-month high of $64.47.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.